FHLC

Fidelity MSCI Health Care Index ETF

HealthcarePSEFidelity ETF
$83.14
$-0.86 (-1.02%)
Delayed ≥20 min · Sep 4, 2026

Key Statistics

Net Assets (AUM)
$324.25M
Expense Ratio
See prospectus
Previous Close
$84.00
Day Range
- – -
52-Week Range
$64.30 – $85.46
Volume
303.36K
Avg Vol (50D)
163.25K
Beta
0.60

Historical Performance

1M
+4.29%
3M
+13.62%
6M
+14.86%
YTD
+12.71%
1Y
+28.08%
3Y
+38.69%
5Y
+30.36%

Total return including reinvested distributions, from adjusted closing prices.

Price History

Price history is being compiled for this fund.

Top Holdings

Eli Lilly & Co 12.13%
Johnson & Johnson 8.94%
AbbVie Inc 6.03%
UnitedHealth Group Inc 5.42%
Merck & Co Inc 4.38%
Amgen Inc 3.01%
Thermo Fisher Scientific Inc 2.91%
Gilead Sciences Inc 2.62%
Intuitive Surgical Inc 2.62%
Abbott Laboratories 2.55%
Pfizer Inc 2.45%
Bristol-Myers Squibb Co 1.99%
Danaher Corp 1.84%
Stryker Corp 1.75%
Vertex Pharmaceuticals Inc 1.75%
CVS Health Corp 1.71%
Medtronic PLC 1.68%
McKesson Corp 1.62%
Boston Scientific Corp 1.38%
Elevance Health Inc 1.35%
Cigna Group/The 1.25%
Regeneron Pharmaceuticals Inc 1.18%
HCA Healthcare Inc 1.12%
Cencora Inc 0.92%
Zoetis Inc 0.82%

Top 25 holdings as of Apr 30, 2026 · source: SEC N-PORT. Full holdings & prospectus →

About FHLC

Investing at least 80% of assets in securities included in the MSCI USA IMI Health Care 25/50 Index. The MSCI USA IMI Health Care 25/50 Index represents the performance of the health care sector in the U.S. equity market. The index consists of U.S. companies that are classified in the health care sector according to the GICS ® . The GICS ® health care sector encompasses two main industry groups. The first group includes companies that manufacture health care equipment and supply or provide health care related services, including distributors of health care products, providers of basic health-care services, and owners and operators of health care facilities and organizations. The second group includes companies primarily involved in the research, development, production and marketing of pharmaceuticals and biotechnology products. Effective December 11, 2025, derivative instruments that provide investment exposure to the investments above or exposure to one or more market risk factors associated with such investments are included in the fund's 80% policy, consistent with the fund's investment policies and limitations with respect to investments in derivatives. Using a representative sampling indexing strategy to manage the fund. "Representative sampling" is an indexing strategy that involves investing in a representative sample of securities that collectively has an investment profile similar to the index. The securities selected are expected to have, in the aggregate, investment characteristics (based on factors such as market capitalization and industry weightings), fundamental characteristics (such as return variability and yield) and liquidity measures similar to those of the index. The fund may or may not hold all of the securities in the MSCI USA IMI Health Care 25/50 Index.

Data for FHLC is aggregated from third-party providers (Tiingo, Nasdaq, Finnhub) and SEC filings, may be delayed at least 20 minutes, and may be incomplete or contain errors. Nothing here is investment advice. Verify with the official prospectus before investing.